ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Statin treatment and COVID-19 mortality

The authors highlight the importance of their study in clarifying and expanding the current understanding of the relationship between COVID-19 and statins.

18 Oct 2021

Women with type 2 diabetes and CVD less likely to reach treatment targets than men, study finds

Women with type 2 diabetes and cardiovascular disease (CVD), or at high risk of developing CVD, are less likely to reach recommended treatment targets than men, according to an international study involving almost 10,000 patients with type 2 diabetes, being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), held online this year (27 Sept-1 Oct). Nevertheless, women were less likely to experience adverse CVD outcomes apart from a stroke.

27 Sep 2021

Neurokinin-1 receptor: a potential drug target for the treatment of COVID-19

An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.

21 Sep 2021

Early treatment with ACE inhibitors improves cardiac outcomes of patients with Becker muscular dystrophy

There is no consensus on when to introduce cardioprotective treatment in patients with Becker muscular dystrophy (BMD), and practice varies widely.

20 Sep 2021

New ESC guidelines for diagnosis and treatment of heart failure published

The European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure are published online today in European Heart Journal.

27 Aug 2021

Antihypertensives may improve survival for patients with colorectal cancer

Common blood-pressure drugs may improve survival for patients with colorectal cancer, a new study suggests.

19 Aug 2021

More popular type of antihypertensive drugs causes slightly more side effects

Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, but the more popular type causes slightly more side effects, finds a multinational observational study led by researchers at Columbia University Vagelos College of Physicians and Surgeons.

26 Jul 2021

Two types of blood pressure drugs provide equal benefits, but side effects differ

People who are just beginning treatment for high blood pressure can benefit equally from two different classes of medicine - angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - yet ARBs may be less likely to cause medication side effects, according to an analysis of real-world data published today in Hypertension, an American Heart Association journal.

26 Jul 2021

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host’s microbiome and secondary infection has also been studied.

8 Jul 2021

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Statins are medications widely used in the management of cardiovascular diseases and metabolic syndrome. Statins help lower serum lipids by blocking HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase), the rate-limiting enzyme of cholesterol biosynthesis.

11 Jun 2021

Study reveals mechanisms by which SGLT2 inhibitors produce renoprotective effect

SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.

8 Jun 2021

Oral antidiabetic medication provides kidney protection in focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare form of kidney inflammation (glomerulonephritis) in which the glomeruli become increasingly scarred (sclerotic), leading to progressive loss of kidney function.

7 Jun 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Researchers develop innovative profiling methods for SARS-CoV-2 infection

A team of researchers from various institutions in the USA used RNA-sequencing data and other methods to profile unique genes and other characteristics associated with SARS-CoV-2 in New York City (NYC).

17 Mar 2021

New guidelines aim to help reduce blood pressure for chronic kidney disease patients

A recommendation for more intensive blood pressure management from an influential global nonprofit that publishes clinical practice guidelines in kidney disease could, if followed, benefit nearly 25 million Americans, according to an analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health.

23 Feb 2021

Two common blood pressure drugs are not tied to increased risk of COVID-19

Research published in the peer-reviewed journal The Lancet Digital Health and co-led by a UCLA Fielding School of Public Health faculty member has found that two widely used types of blood pressure drugs are not tied to an increased risk of COVID-19 infection or complications.

18 Jan 2021

Patient with hypertension or cardiovascular diseases experienced critical disease progression with COVID-19

COVID-19 patients who also suffer from high blood pressure are more likely to fall severely ill with the disease, which also leaves them at greater risk of death.

11 Jan 2021